2
Participants
Start Date
March 29, 2018
Primary Completion Date
December 11, 2018
Study Completion Date
December 11, 2018
Olmutinib
"600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
National Cancer Center, Gyeonggi-do
The Catholic Univ. of Korea Bucheon St.Mary's Hospital, Gyeonggi-do
The Catholic Univ. of Korea St.Vincent's Hospital, Gyeonggi-do
The Catholic Univ. of Korea Uijeongbu St.Mary's Hospital, Gyeonggi-do
Gachon University Gil Medical Center, Incheon
The Catholic Univ. of Korea Incheon St.Mary's Hospital, Incheon
Samsung Medical Center, Seoul
The Catholic Univ. of Korea Seoul St.Mary's Hospital, Seoul
Lead Sponsor
Hanmi Pharmaceutical Company Limited
INDUSTRY